SCHEMBL1016690

SCHEMBL1016690

CNc1nc(Cl)nc2c1c(I)cn2S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
YTHDC1 Q96MU7 2/20 0.41
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 3/20 0.38
HTT P42858 2/20 0.38
CYP3A4 P08684 2/20 0.38
HPGD P15428 2/20 0.38
CYP2C19 P33261 2/20 0.38
MAPT P10636 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
POLB P06746 1/20 0.36
ALDH3A1 P30838 1/20 0.36
NOD1 Q9Y239 1/20 0.36
RAPGEF4 Q8WZA2 1/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CYP1A2 P05177 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25204252 0.86 CA1 (0.43) YTHDC1ALDH1A1KDM4EHTTCYP3A4
SCHEMBL1019247 0.86 GPR6 (0.37) YTHDC1ALDH1A1HTTCYP3A4MAPT
SCHEMBL1017371 0.85 ALDH1A1 (0.41) ALDH1A1KDM4EHTTHPGDMAPT
SCHEMBL1020660 0.84 HDAC1 (0.36) ALDH1A1MAPTPOLBCA1CA2
SCHEMBL25221204 0.84 ALDH1A1 (0.38) ALDH1A1KDM4EHTTHPGDMAPT
SCHEMBL31052340 0.84 ALDH1A1 (0.38) ALDH1A1KDM4EHTTHPGDMAPT
SCHEMBL31052299 0.83 MEN1 (0.42) ALDH1A1KDM4EHTTMAPTL3MBTL1
SCHEMBL1019454 0.83 MAPT (0.46) YTHDC1ALDH1A1KDM4ECYP3A4HPGD
SCHEMBL25523142 0.83 ALDH1A1 (0.33) YTHDC1ALDH1A1HTTHPGDMAPT
SCHEMBL1018097 0.82 MAPT (0.44) ALDH1A1KDM4EMAPTPOLBCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed
EP-2271631-B1 INHIBITORS OF PROTEIN KINASES PORTOLA PHARM INC (US) 2018-07-04 EP disclosed
US-9139581-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9139581-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9139581-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-20130029944-A1 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2013-01-31 US disclosed
US-20130029944-A1 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2013-01-31 US disclosed
US-20130029944-A1 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2013-01-31 US disclosed
US-8258144-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-09-04 US disclosed
US-8258144-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-09-04 US disclosed
US-8258144-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-09-04 US disclosed
EP-2271631-A2 INHIBITORS OF PROTEIN KINASES Portola Pharmaceuticals, Inc. (US) 2011-01-12 EP disclosed
US-20090298823-A1 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-03 US disclosed
US-20090298823-A1 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-03 US disclosed
US-20090298823-A1 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-03 US disclosed
WO-2009131687-A2 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2009-10-29 WO disclosed
WO-2009131687-A2 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029944-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK2 YTHDC1 3464/4885ALDH1A1 3049/4885KDM4E 1124/4885
US-20090298823-A1 Inhibitors of protein kinases SYK, BTK, JAK2 YTHDC1 3464/4885ALDH1A1 3049/4885KDM4E 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.